Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

C. Genova

h-index 37 View on Semantic Scholar

We have 5 of 307 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity

Pleural mesothelioma (PM) is a rare and aggressive cancer with limited treatment options and poor prognosis. Unlike other thoracic cancers responding well to immunotherapy, PM typically lacks key predictive biomarkers such as Programmed Death-Ligand 1 (PD-L1) tumor expression. Nonetheless, immune checkpoint inhibitors...

L. Cerbone, Alessia Garau, Andrea Balossino et al. · 0 citations
Open access Sep 2026

Host-derived immunometabolic biomarkers identify prognostic profiles under immunotherapy in advanced NSCLC: the SARC-LUNG study

Immune checkpoint inhibitors (ICIs) improve outcomes in advanced non-small cell lung cancer (NSCLC), but predictive biomarkers remain limited. Host-derived immunometabolic factors may modulate response to ICIs. In the prospective SARC-LUNG study, 40 patients with advanced NSCLC treated with first-line ICIs...

A. De Giglio, Maria Conte, Simona Coco et al. · 0 citations
Open access Sep 2026

Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database

Osimertinib exhibited meaningful differences in efficacy and resistance mechanisms across distinct ucEGFR mut, and ex19 delins showed comparable survival outcomes and resistance patterns to classical ex19 deletions, albeit with heterogeneous osimertinib sensitivity depending on the deletion–insertion starting codon.

G. Farinea, A. Mogavero, A. Vitale et al. · 0 citations
Open access Aug 2026

AI-HOPE lung cancer: a multicenter real-world registry integrating artificial intelligence for metastatic non-small-cell lung cancer

By combining structured clinical variables and multimodal imaging data, the AI-HOPE Lung Cancer study aims to support refined risk stratification and treatment personalization, ultimately facilitating the responsible integration of AI into routine thoracic oncology practice.

F. Ogliari, M. Ferrara, J. Huijs et al. · 0 citations
Review Open access Jul 2026

Recent advances in EGFR-targeted therapies for non-small cell lung cancer

This review discusses recent advances in EGFR-targeted therapies within the molecular landscape of classical and uncommon EGFR mutations, focusing on frontline intensification strategies in metastatic disease—specifically TKI combinations with chemotherapy or bispecific antibodies or bispecific antibodies—and emerging...

L. Lucente, Lucrezia Barcellini, Beatrice Ramella Pollone et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.